stock markets for traders. period
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
idix > look at these hedges http://www.nasdaq.com/symbol/idix/institutional-holdings
idix > they run in January on similar news to $15
playin' $IDIX
MRI Interventions, Inc. (MRIC) today announced the issuance of U.S. Patent No. 8,175,677, which further bolsters MRI Interventions’ position as a leader in the market for MRI-guided medical procedures.
With the new patent, the company’s patent estate now includes 66 issued patents and over 100 pending patent applications, both United States and foreign. The company’s patents and pending applications cover, among other technologies, reusable hardware components, disposable components and integrated software that work in conjunction with magnetic resonance imaging (MRI) to guide the delivery of various therapies to the brain.
“MRI Interventions is at the forefront of MRI-guided medical procedures. The new patent is an important addition to our substantial patent portfolio in this growing field,” stated Kimble Jenkins, CEO of MRI Interventions.
The new patent relates to the company’s SmartFrame® device, an MRI-compatible adjustable trajectory frame that is an integral component of the company’s ClearPoint® Neuro Intervention System. The ClearPoint System represents a technological advancement in neurosurgery by allowing surgeons for the first time to see inside the brain during procedures using MRI. The SmartFrame works in conjunction with the ClearPoint software and serves as an MRI-visible guide to facilitate the precision delivery of devices to locations in the brain during minimally invasive surgical procedures.
The SmartFrame device and the ClearPoint System are in commercial use and have been utilized in a variety of neurological procedures, including placement of electrodes and insertion of biopsy needles, focal ablation devices, and injection catheters for the delivery of drugs.
Recent insider buys on open market:
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8661745
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8671271
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8674235
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8675911
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8675983
Shares Bought 43,998 Sold 0
TransDate Filer Ownership Type Price Shares
Jun 14, 2012 PIETRANGELO MICHAEL Director direct Buy 0.95 5,000
Jun 14, 2012 CONWAY BRUCE C. Director indirect Buy 0.90 to 1.00 3,000
Jun 14, 2012 CONWAY BRUCE C. Director indirect Buy 1.00 4,000
Jun 13, 2012 CONWAY BRUCE C. Director indirect Buy 1.10 to 1.45 6,000
Jun 12, 2012 CONWAY BRUCE C. Director indirect Buy 1.20 2,250
Jun 6, 2012 PIETRANGELO MICHAEL Director direct Buy 1.458 10,000
MD Anderson Performs First MRI-Guided Brain Biopsy Using ClearPoint(R) System
Procedure Represents Newest Use of MRI Interventions' Next-Generation Technology
MEMPHIS, Tenn., June 5, 2012 (GLOBE NEWSWIRE) -- MRI Interventions, Inc. (OTCBB:MRIC) today announced that the first MRI-guided brain biopsy using the company's ClearPoint(R) System has been performed at MD Anderson in Houston, Texas by neurosurgeon Dr. Ashwin Viswanathan, working with Dr. Sujit Prabhu. The MRI-guided brain biopsy represents the newest use of the ClearPoint System, which has already been successfully used by neurosurgeons in the United States for the insertion of electrodes and catheters in the brain.
MRI Interventions' ClearPoint System is an integrated system of reusable components, disposable components and intuitive, menu-driven software. It provides guidance for the placement and operation of instruments during neurological procedures performed within the magnetic resonance imaging (MRI) environment. Using the ClearPoint system, a physician sees and selects a neurological target, aims MRI Interventions' targeting device, and watches via MRI as the surgical instrument is advanced to the target. The ClearPoint system is intended to be used as an integral part of procedures, such as biopsies and catheter and electrode insertions, which have traditionally been performed using stereotactic methods, and the system is designed to allow those procedures to be performed in a hospital's existing MRI suite.
"The system worked well," said Dr. Prabhu. "The clear advantage is confirming the position of the needle tip prior to a biopsy and also identifying a safe trajectory to the lesion."
The biopsy needle used in the procedure at MD Anderson was a brain biopsy needle manufactured by Ad-Tech Medical Instrument Corporation.
MRI Interventions Commences Trading as a Public Company Under the Symbol “MRIC”
CEO announces trading and provides company update in letter released to stockholders
MRI Interventions (OTCBB:MRIC.OB) CEO, Kimble Jenkins, has released the following letter to stockholders:
Dear Fellow Stockholders:
I am pleased to report to you several significant, positive developments at MRI Interventions.
We are cleared for trading - MRI Interventions will begin trading as a public company on Monday, under the symbol “MRIC”. This achievement is the result of many months of work, including extensive regulatory filings with the Securities and Exchange Commission and a detailed review process conducted by the Financial Industry Regulatory Authority.
We made the cover - Our ClearPoint® Neuro Intervention System reached a significant milestone in March, being featured on the cover of the Journal of Operative Neurosurgery. As a leading peer-reviewed journal for neurosurgeons, we are very pleased with this recognition. You can access an abstract of the journal article by clicking on the following link: http://journals.lww.com/neurosurgery/toc/2012/03001
Installations are growing - ClearPoint systems are installed at a growing number of hospitals, including many of the leading neurosurgical centers in the country. ClearPoint sites include UCSF Medical Center, Emory Healthcare, Memorial Sloan Kettering Cancer Center, the National Institutes of Health, Henry Ford Health Systems, MD Anderson, University of Pittsburg Medical Center, and University of Wisconsin among others. We are making progress outside the US as well. At the end of last year, we completed our first installation in Europe and expect to open additional ClearPoint sites in Europe over the coming quarters.
We are making a difference - ClearPoint neuro procedures are continuing to go very well. Neurosurgeons have now used the ClearPoint system as the minimally invasive neurosurgical platform in their treatment of patients suffering from a range of neuro diseases including Parkinson’s disease, Dystonia, Pediatric Dystonia, Brain tumors, Epilepsy and Tourette’s syndrome. We are gratified to have an opportunity to benefit a growing number of patients.
For a more detailed overview of the Company, I invite you to review our Investor Presentation, which can be found at the following link: http://ir.stockpr.com/mriinterventions/presentations. Also, if you haven’t had a chance to see a demonstration of our ClearPoint system, please go to: http://www.mriinterventions.com/clearpoint/demonstration-video.
As we begin this exciting new chapter in the life of the company, I again want to thank our stockholders for their trust and confidence. With your support, we look forward to continuing our efforts to change people’s lives with our innovative products and technologies.
Very truly yours,
Kimble L. Jenkins
Chief Executive Officer
About MRI Interventions, Inc.
Founded in 1998, MRI Interventions, Inc. is creating innovative platforms for performing the next generation of minimally invasive surgical procedures in the brain and heart. Utilizing a hospital’s existing MRI suite, the company’s FDA-cleared ClearPoint® system is designed to enable a range of minimally invasive procedures in the brain. In partnership with Siemens Healthcare, MRI Interventions is developing the ClearTrace™ system to enable MRI-guided catheter ablations to treat cardiac arrhythmias, including atrial fibrillation. Building on the imaging power of MRI, the company’s interventional platforms strive to improve patient care while reducing procedure costs and times. MRI Interventions is also working with Boston Scientific Corporation to incorporate its MRI-safety technologies into Boston Scientific's implantable leads for cardiac and neurological applications. For more information, please visit www.MRIinterventions.com.
lol
good business idea ;)
Apple announced today that it has developed a breast implant that can store and play music!
The iTit will cost from $499 to $699, depending on cup and speaker size.
This is considered a major social breakthrough because for generations women have been complaining about men staring at their breasts and not listening to them.
SGYP
FFN > shorts 're playing this show...
FB > delay...
FB should be open at 11...
FFN > 3 bucks 2day?
weeeeeeeeeeeeeeeee
FFN, buddy; as soon as FB starts trading - this one will go ballistic...
FFN > squeeze...
FFN > traded 5.4M shares out of 8.3M float
FFN buddy
VIBE > gappin'
lol
gonna be fun is this old pos (RSHN) gets a volume
Apple Rush® Company to Issue Dividends
STOCKHOLDERS TO OWN TRADEMARKS DIVIDEND NOTICE
GLENVIEW, Ill., May 15, 2012 /PRNewswire/ -- Apple Rush® Co., Inc. (APRU.PK). The company is providing a dividend to all the Apple Rush Co., Inc. stockholders and to all the RushNet Inc. (RSHN.PK) stockholders in the form of ownership two newly formed companies to be public and OTC reporting.
Rush Holding Company, in the process of Wyoming incorporation, will own the following trademarks: APPLE RUSH, GINSENG RUSH and HARD RUSH. The new HARD RUSH is a juice and alcohol beverage that is in product development.
The company is making an application for trademark approval. In addition to a complete ownership in the trademarks, this new Wyoming Company shall be a public entity and will also own all of the Illinois distributorship, Corr Brands, Inc. This company owns and controls basic alcohol permits to import and distribute beer and wine in the State of Illinois. Presently the license to distribute Apple Rush is given to Apple Rush, Inc. The license will be transferred to Rush Holding Company and Apple Rush, Inc. will continue to sell the brand, Apple Rush, as an exclusive agent in the Americas.
A second Wyoming corporation is also being formed, Capital Rush Inc., and will be a public company. Capital Rush Inc. will be the financial arm to finance the operations of the companies marketing and selling the drinks and products being offered by Rush Holding Company for distribution in Americas.
Capital Rush Inc. will also invest in other quality beverages and healthy foods with vegan, gluten free and kosher varieties
The previous license for Ginseng Rush held by RushNet Inc. will transfer to Apple Rush Co., Inc for distribution along with the Apple Rush Brand.
Robert Corr, President and CEO, adds, "The Apple Rush and RushNet stockholders have requested that we transfer all of the trademarks and licenses into one holding company, which would then be owned by the Apple Rush and RushNet shareholders. Accordingly, the process is underway. Management's expectation is this combination will confirm to shareholders of both companies that management intends to unite the companies and capitalize on the brand strength and build and protect shareholder value and allow for well capitalized growth.
email came from the constantcontact hototc account - headers are intact
great calls!
DGRI > looking for a dip
morning boss ;)
that's my target ;)
$DVAX 4.13 weeeeeeeeeeeee
DVAX > bought some; crap should be back to $4.50 in a week or so...
VERT is our friend. lol
dump-a-rama, isn't it? lol
Trovagene, Inc., Announces Issuance of European Patent for Detection of Pathogenic Infections
SAN DIEGO, May 10, 2012 /PRNewswire/ -- Trovagene, Inc. (Pink Sheets: TROV), a developer of trans-renal molecular diagnostics, announced it has received notice of issuance of European Patent No. 2216416 entitled "Methods for Detection of Nucleic Acid Sequences in Urine."
This patent pertains to the detection of pathogenic infections from urine specimens and complements previously issued U.S. patents, including the reissued patent RE39920 for the detection of nucleic acids from viral, bacterial, fungal, mycoplasma, and protozoan infections in urine samples. Other previously issued, related patents include EP0920539 for detection of fetal nucleic acids from maternal urine, and EP1634966 for detection of cancer-specific nucleic acids from a patient's urine sample.
"This patent is a valuable addition to our fundamental IP portfolio," said Dr. Antonius Schuh, chief executive officer of Trovagene. "It provides a basis for diagnosing and monitoring viral, bacterial or parasitic infections using a sample that is stable, easy to collect, and truly non-invasive. This provides a convenient method for sample collection anywhere in the world, whether in industrialized or developing countries."
http://www.otcmarkets.com/edgar/GetFilingHtml?FilingID=8600488
We are offering 4,500,000 shares of our common stock pursuant to this prospectus. We expect to effect a 1-for-5 reverse stock split of our outstanding common stock just prior to the date of this prospectus.
Our common stock is presently quoted on the OTC QB under the symbol “TROV.PK”. We have applied to list our common stock on The NASDAQ Capital Market under the symbol “TROV”. On May 4, 2012, the last reported sale price for our common stock on the OTC QB was $4.65 per share after giving pro forma effect to the 1-for-5 reverse stock split of our outstanding common stock.
$TROV $1.09 52W High
blue skies with the volume...
impressive volume 4sho
lol
nicezzz
$TROV > $1 new 52W high
they should come up with "short squeeze" topic... will help much more than any technology BS...